Neurotrophic Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major neurotrophic keratitis markets reached a value of US$ 137.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 248.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.51% during 2024-2034.
The neurotrophic keratitis market has been comprehensively analyzed in IMARC's new report titled "Neurotrophic Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neurotrophic keratitis is a degenerative corneal condition caused by sensory innervation impairment in the cornea. Based on the severity of the disease, it can be classified into stages I, II, and III. Neurotrophic keratitis is characterized by reduced or absent corneal sensation, resulting in spontaneous epithelial breakdown, poor corneal recovery, and, eventually, the development of corneal ulceration, melting, and perforation. The symptoms of this ailment can vary but typically involve redness, stinging, burning, or irritation of the eyes, along with mucus discharge and decreased or blurred vision. The other rare symptoms associated with this condition include sensitivity to light and discomfort wearing contact lenses. The diagnosis of the ailment generally involves a comprehensive eye examination, such as a visual acuity test and a detailed evaluation of the cornea. Various specialized tests, including corneal sensitivity testing and confocal microscopy, are used to confirm the diagnosis and assess the severity of the disease. In some cases, numerous imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), may be necessary to rule out other underlying conditions.
The rising incidences of trigeminal nerve damage caused by several associated risk factors, such as infectious disorders like herpes simplex virus (HSV), eye or facial region trauma, systemic diseases, including diabetes mellitus and multiple sclerosis, etc., are primarily augmenting the neurotrophic keratitis market. In addition to this, the widespread adoption of nerve growth factor (NGF) eye drops as a novel treatment option since it improves corneal sensitivity, lowers corneal ulceration, and enhances vision in patients is further creating a positive outlook for the market. Moreover, the increasing utilization of amniotic membrane transplantation, which utilizes growth factors and anti-inflammatory cytokines that promote corneal healing and reduce scarring, for treating neurotrophic keratitis, is also acting as a significant growth-inducing factor. Additionally, the inflating application of non-pharmacological treatments for neurotrophic keratitis, such as therapeutic scleral and corneal contact lenses, to stimulate epithelial healing of the cornea and decrease corneal complications is further propelling the market growth. Besides this, the introduction of new formulations of corticosteroids for treating the disease, including loteprednol etabonate, which reduces the risk of side effects like elevated intraocular pressure, is expected to drive the neurotrophic keratitis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the neurotrophic keratitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neurotrophic keratitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neurotrophic keratitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neurotrophic keratitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neurotrophic keratitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neurotrophic keratitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neurotrophic keratitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neurotrophic keratitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neurotrophic keratitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with neurotrophic keratitis across the seven major markets?
What is the size of the neurotrophic keratitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neurotrophic keratitis?
What will be the growth rate of patients across the seven major markets?
Neurotrophic Keratitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neurotrophic keratitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neurotrophic keratitis market?
What are the key regulatory events related to the neurotrophic keratitis market?
What is the structure of clinical trial landscape by status related to the neurotrophic keratitis market?
What is the structure of clinical trial landscape by phase related to the neurotrophic keratitis market?
What is the structure of clinical trial landscape by route of administration related to the neurotrophic keratitis market?
The neurotrophic keratitis market has been comprehensively analyzed in IMARC's new report titled "Neurotrophic Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neurotrophic keratitis is a degenerative corneal condition caused by sensory innervation impairment in the cornea. Based on the severity of the disease, it can be classified into stages I, II, and III. Neurotrophic keratitis is characterized by reduced or absent corneal sensation, resulting in spontaneous epithelial breakdown, poor corneal recovery, and, eventually, the development of corneal ulceration, melting, and perforation. The symptoms of this ailment can vary but typically involve redness, stinging, burning, or irritation of the eyes, along with mucus discharge and decreased or blurred vision. The other rare symptoms associated with this condition include sensitivity to light and discomfort wearing contact lenses. The diagnosis of the ailment generally involves a comprehensive eye examination, such as a visual acuity test and a detailed evaluation of the cornea. Various specialized tests, including corneal sensitivity testing and confocal microscopy, are used to confirm the diagnosis and assess the severity of the disease. In some cases, numerous imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), may be necessary to rule out other underlying conditions.
The rising incidences of trigeminal nerve damage caused by several associated risk factors, such as infectious disorders like herpes simplex virus (HSV), eye or facial region trauma, systemic diseases, including diabetes mellitus and multiple sclerosis, etc., are primarily augmenting the neurotrophic keratitis market. In addition to this, the widespread adoption of nerve growth factor (NGF) eye drops as a novel treatment option since it improves corneal sensitivity, lowers corneal ulceration, and enhances vision in patients is further creating a positive outlook for the market. Moreover, the increasing utilization of amniotic membrane transplantation, which utilizes growth factors and anti-inflammatory cytokines that promote corneal healing and reduce scarring, for treating neurotrophic keratitis, is also acting as a significant growth-inducing factor. Additionally, the inflating application of non-pharmacological treatments for neurotrophic keratitis, such as therapeutic scleral and corneal contact lenses, to stimulate epithelial healing of the cornea and decrease corneal complications is further propelling the market growth. Besides this, the introduction of new formulations of corticosteroids for treating the disease, including loteprednol etabonate, which reduces the risk of side effects like elevated intraocular pressure, is expected to drive the neurotrophic keratitis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the neurotrophic keratitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neurotrophic keratitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neurotrophic keratitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neurotrophic keratitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neurotrophic keratitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neurotrophic keratitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neurotrophic keratitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neurotrophic keratitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neurotrophic keratitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with neurotrophic keratitis across the seven major markets?
What is the size of the neurotrophic keratitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neurotrophic keratitis?
What will be the growth rate of patients across the seven major markets?
Neurotrophic Keratitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neurotrophic keratitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neurotrophic keratitis market?
What are the key regulatory events related to the neurotrophic keratitis market?
What is the structure of clinical trial landscape by status related to the neurotrophic keratitis market?
What is the structure of clinical trial landscape by phase related to the neurotrophic keratitis market?
What is the structure of clinical trial landscape by route of administration related to the neurotrophic keratitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROTROPHIC KERATITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 NEUROTROPHIC KERATITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROTROPHIC KERATITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.5 Epidemiology by Gender (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 NEUROTROPHIC KERATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROTROPHIC KERATITIS - UNMET NEEDS
10 NEUROTROPHIC KERATITIS - KEY ENDPOINTS OF TREATMENT
11 NEUROTROPHIC KERATITIS - MARKETED PRODUCTS
11.1 List of Neurotrophic Keratitis Marketed Drugs Across the Top 7 Markets
11.1.1 Oxervate (Cenegermin) - Dompe Farmaceutici
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NEUROTROPHIC KERATITIS - PIPELINE DRUGS
12.1 List of Neurotrophic Keratitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Udonitrectag - Recordati Rare Diseases
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROTROPHIC KERATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROTROPHIC KERATITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROTROPHIC KERATITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neurotrophic Keratitis - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Neurotrophic Keratitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Neurotrophic Keratitis - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Neurotrophic Keratitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neurotrophic Keratitis - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Neurotrophic Keratitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neurotrophic Keratitis - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Neurotrophic Keratitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neurotrophic Keratitis - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Neurotrophic Keratitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neurotrophic Keratitis - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Neurotrophic Keratitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neurotrophic Keratitis - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Neurotrophic Keratitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neurotrophic Keratitis - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Neurotrophic Keratitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Neurotrophic Keratitis - Access and Reimbursement Overview
16 NEUROTROPHIC KERATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROTROPHIC KERATITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROTROPHIC KERATITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROTROPHIC KERATITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 NEUROTROPHIC KERATITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROTROPHIC KERATITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.5 Epidemiology by Gender (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 NEUROTROPHIC KERATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROTROPHIC KERATITIS - UNMET NEEDS
10 NEUROTROPHIC KERATITIS - KEY ENDPOINTS OF TREATMENT
11 NEUROTROPHIC KERATITIS - MARKETED PRODUCTS
11.1 List of Neurotrophic Keratitis Marketed Drugs Across the Top 7 Markets
11.1.1 Oxervate (Cenegermin) - Dompe Farmaceutici
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NEUROTROPHIC KERATITIS - PIPELINE DRUGS
12.1 List of Neurotrophic Keratitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Udonitrectag - Recordati Rare Diseases
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROTROPHIC KERATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROTROPHIC KERATITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROTROPHIC KERATITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neurotrophic Keratitis - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Neurotrophic Keratitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Neurotrophic Keratitis - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Neurotrophic Keratitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neurotrophic Keratitis - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Neurotrophic Keratitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neurotrophic Keratitis - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Neurotrophic Keratitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neurotrophic Keratitis - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Neurotrophic Keratitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neurotrophic Keratitis - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Neurotrophic Keratitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neurotrophic Keratitis - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Neurotrophic Keratitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Neurotrophic Keratitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neurotrophic Keratitis - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Neurotrophic Keratitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Neurotrophic Keratitis - Access and Reimbursement Overview
16 NEUROTROPHIC KERATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROTROPHIC KERATITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROTROPHIC KERATITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
